Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility

Hong Kong's biopharmaceutical sector experienced a notable uptick, with several key stocks showing significant gains. According to Jin10, WuXi Biologics (02268.HK) surged over 8%, while WuXi AppTec (02359.HK) rose more than 7%. Additionally, CanSino Biologics (02162.HK) increased by over 5%, and InnoCare Pharma (09969.HK) climbed nearly 4%. Other stocks, including Rongchang Biopharma (09995.HK), also followed the upward trend. This movement reflects a broader market volatility impacting the biopharmaceutical industry in Hong Kong.